FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to oncology, and can be used for assessing the risk of developing an unfavorable outcome in the patients with non-small cell lung cancer (NSCLC). Method involves examination of primary tumor tissue taken during surgical intervention, in which chymotrypsin-like (ChPA) and caspase-like (CPA) proteasome activity. With ChPA higher than 48.8*103 unit/mg of protein and CPA above 31.2*103 unit/mg of protein predict high probability of unfavorable outcome.
EFFECT: use of the invention enables higher prediction accuracy, high sensitivity and specificity suggesting a possible clinical outcome in the patients NSCLC and to calculate the risk of unfavorable outcome after radical surgery.
1 cl, 1 tbl, 3 dwg, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| METHOD FOR PREDICTION OF RISK OF DEVELOPING DISTANT METASTASES IN PATIENTS WITH OPERABLE FORMS OF BREAST CANCER WITH METASTASES IN REGIONAL LYMPH NODES | 2020 |
|
RU2733697C1 |
| METHOD FOR PREDICTING THE OUTCOME OF A DISEASE IN PATIENTS WITH LUMINAL AND THRICE NEGATIVE BREAST CANCER IN PATIENTS WHO DID NOT RECEIVE CHEMOTHERAPY OR HORMONE THERAPY IN THE NEOADJUVANT REGIMEN | 2017 |
|
RU2648523C1 |
| METHOD FOR EVALUATING THE DEGREE OF RISK OF ADVERSE EVALUATION OF DISEASE IN PATIENTS WITH GASTRIC CANCER | 2016 |
|
RU2662085C1 |
| METHOD FOR PREDICTION OF RISK OF RECURRENT DISEASE OF SQUAMOUS CELL LUNG CANCER OF STAGE IIB-IIIA IN PATIENTS RECEIVING ADJUVANT POLYCHEMOTHERAPY AFTER RADICAL SURGERY | 2023 |
|
RU2815575C1 |
| METHOD OF DETERMINING THE RISK OF MALIGNANT TRANSFORMATION OF EPITHELIAL CELLS OF THE LARYNX IN PATIENTS WITH PRECANCEROUS DISEASES OF THE LARYNX | 2022 |
|
RU2803858C1 |
| METHOD FOR PREDICTION OF CLINICAL OUTCOME OF MUSCULO-INVASIVE BLADDER CANCER FOLLOWING COMBINATION THERAPY | 2012 |
|
RU2538632C2 |
| METHOD FOR DISTANT METASTASES DEVELOPMENT RISK DEGREE DETERMINATION FOR PATIENTS WITH COLON CANCER | 2016 |
|
RU2623119C1 |
| METHOD FOR PREDICTION OF DEVELOPING HAEMATOGENOUS METASTASES FOLLOWING COMBINED TREATMENT OF KIDNEY CANCER | 2013 |
|
RU2528100C1 |
| METHOD FOR PREDICTION OF DEVELOPING LYMPHOGENIC METASTASES IN SQUAMOUS CELL CARCINOMA OF HEAD AND NECK FOLLOWING COMBINATION THERAPY | 2013 |
|
RU2527338C1 |
| METHOD FOR PREDICTION OF DISEASE OUTCOME IN PATIENTS WITH GASTRIC CANCER AFTER SURGICAL MANAGEMENT | 2018 |
|
RU2696054C1 |
